Presentation made by Aagami during Illinois Science and Technology Park Event

Realizing Possibilities, Together
Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
India Lifesciences Industry:
Landscape & Opportunities for IL Companies
© Aagami, Inc. 2016 | All rights reserved | www.aagami.com
Dinesh Jain, Founder CEO, Aagami Inc.

 India – an Introduction
 IN Life sciences Industry Snapshot
 Major centers of Life sciences in India
 Major Deals and Investments Involving Indian companies
 India IPR Scenario
 Business and Cultural Differences
 Benefits of Partnering with Indian companies
 Introduction of Aagami, Inc.
2
Table of Contents
Note : These are some of the deals which Aagami Market Research Team have sourced from Publicly available data and
hence not exhaustive

3
INDIA – An Economic Introduction
 8000 year old civilization (even older than Egypt and Mesopotamia)
 The 2nd most populous(with over 1.32 billion people), 7th largest (by area)
 Indian economy is the world’s 3rd largest in PPP (Purchase Power Parity) and 7th
largest by nominal GDP .
 The Indian economy would become the world's 3rd-largest economy by 2025
 India also topped the World Bank’s growth outlook for 2015-16 growth of 7.6% in
2015-16 and expected to grow 7.7-8.0% in 2016-17.
 Total transaction value of M&A involving Indian companies stood at US$ 26.3
billion with 930 deals in 2015. The total value of M&As involving Indian companies
surged nearly 63 per cent to ₹507 billion ($7.8 billion) in the first three months of
2016.
 Total private equity (PE) investments in India for 2015 reached a record high of
₹1,267.5 billion (US$ 19.5 billion) through 159 deals, according to the PwC
MoneyTree India report.
 During FY 2015, India received the FDI equity inflow from USA of ₹228 billion
(USD 3.51 billion). Commitment of US$42billion (2015-2017) from USA
organisations.
Source: Aagami Business and Market Research and Authoritative sources such as http://www.ibef.org/economy/foreign-direct-investment.aspx, See more at:
http://www.ibef.org/economy/indian-economy-overview#sthash.InZGWgd8.dpuf

Source: Indian Economy At a Glance". Retrieved 2015-10-09. https://principles-of-economics-and-
business.blogspot.in/2015/09/indian-economy-at-glance.html, http://www.ibef.org/economy/indian-economy-
overview#sthash.InZGWgd8.dpuf, IMF
Key Parameters Value Year
GDP ₹156 trillion (USD 2.40 trillion) 2016
GDP Growth 7.6% 2016
Inflation 5.39% May 2016
GDP per Capita (PPP) USD 5,900 2015
Foreign Direct Investment Inflow USD 63 billion 2015
Foreign Direct Investment outflow
(Jan-Feb 2016)
₹ 325 billion (USD 5 billion) 2016
Global consumer confidence Index
created by Nielsen
Rank #1 Dec 2015
Indian Economy at a Glance
Economic
Growth
Projections
 India is placed among the top three countries with the most number of
billionaires in the world.
 India has 97 billionaires, and their combined wealth adds up to $266
billion.
4

India is the 3rd largest
Pharma market by volume
and 10th in terms of value
globally.
Every 3rd pill in the world, is
Made in INDIA.
Largest Provider of Generic
medicines Globally (20%)
Over 20,000 pharmaceuticals
and biotech companies.
More than 550 US FDA
Approved facilities, highest
for any country outside the
US
India Pharma is expected to
expand at a CAGR of 12.89%
to reach USD55 billion by
2020 (conservative
projection).
The drugs and pharma
sector attracted cumulative
FDI inflows worth ₹874.25
billion (US$ 13.45 billion)
between April 2000 and
Dec2015
More than 60,000
distributors and about
800,000 pharmaceuticals
retailers.*
Approval time for new
facilities has been drastically
reduced.
Source: Dec 2015-India Brand Equity Foundation www.ibef.org; http://www.tradingeconomics.com/india/exports-of-pharmaceutical-products
Lifesciences Industry in India: Fast growing and Regulated – 1 of 2
5

More than top 50 Indian
companies have presence in
the regulated market (US,
Canada, Western EU and
Japan).
More than 100 companies
from India are present in 50+
countries.
Indian healthcare market is
₹6,500 billion (USD100
billion) (Dec 2015)
Healthcare sector is
expected to reach ₹16,250
billion (USD 280 billion) by
2020.
Growing at a CAGR of 17%
The hospital and diagnostic
centers attracted FDI worth
₹221.6 billion (US$ 3.41
billion) between April 2000
and Dec2015
Approx. 50% of the essential
medicines that UNICEF
distributes in emerging
countries come from India
Indian medical tourism is
pegged at ₹195 billion (US$ 3
billion) per annum (Dec
2015)
Domestic formulation
market stood at ₹685 billion
(US$ 10.54 billion)
India's filing of Drug Master
Files (DMF's) with USFDA is
among the highest in the
world.
Source: Dec 2015-India Brand Equity Foundation www.ibef.org; http://www.tradingeconomics.com/india/exports-of-pharmaceutical-products
6
Lifesciences Industry in India: Fast growing and Regulated – 2 of 2

Cost Efficiency
• Low cost of production and R&D boosts efficiency of
Indian pharma companies
• India’s cost of production is approximately 60 per
cent lower than that of the US and almost half of
that of Europe
• Due to lower cost of treatment, India is emerging as
a leading destination for medical tourism
Economic Drivers
• Economic prosperity to improve drug affordability
• Increasing penetration of health insurance
• With increasing penetration of chemists, especially in
rural India, OTC drugs will be readily available
Diversified Portfolio
• Accounts for over 10 per cent of the global
pharmaceutical production
• Over 60,000 generic brands across 60 therapeutic
categories.
• Manufactures more than 500 different APIs
• 49 per cent of all drug master filings from India is
registered in the USA
Policy Support
•Government unveiled ‘Pharma Vision 2020’ aimed
at making India a global leader in end-to-end drug
manufacturer
•Reduced approval time for new facilities to boost
investments
•100 per cent FDI is allowed under automatic route
India
Pharma
INDIA PHARMA – Key Features
Source: IBEF Pharma Report Jan 2016
Parameters Total cost in
%
Cost in US 100%
Production cost in
India
50%
R&D cost in India 30%
Clinical trial cost
in India
40%
Relative Cost advantage in
India(%) [Thumb Rule]
7

India Pharma by Type of Drugs and Therapy Areas
Source: IBEF Pharma Report Jan 20168

Notable Trends from India Pharma
R&D
• Indian companies
spend 8-11 % of
their total revenue
on R&D
• Expenditure on
R&D has increased
due to the
introduction of
product patents;
companies are
developing new
technologies and
drugs to boost
sales
Export Revenue
• India’s
pharmaceutical
export market is
thriving due to
strong presence in
the generics space
• Pharma exports
reached USD15
billion in 2015 and
estimated to reach
USD18.02 billion in
2016
Joint Ventures
• Multinational
companies are
collaborating with
Indian pharma
firms to develop
new drugs
Global Expansion
by Indian
companies
are expanding
globally by
mergers,
acquisitions, and
other partnerships.
are not only cash
rich but also
hungry to compete
with the Best of
the West
Less Time for
Approval
• In order to
compete with
global players in
pharmaceutical
industries,
approval process of
drugs have been
simplified by the
authorities and
approval time for
new facilities has
been drastically
reduced
9

Majority of Indian states host Life Science business centres in India (1/2)
City Major Companies
Mumbai Sun Pharma, Lupin, Wockhardt, Glenmark, USV, Ipca, Indoco Remedies, Bharat Serum and Vaccines Ltd, Cipla,
FDC, Most MNCs
Ahmedabad Zydus, Cadila, Intas, Torrent, Dishman, Helios, Claris Lifesciences
Hyderabad Dr.Reddy’s, Aurobindo, Suven LifeSciences, Divi’s, Hetero, Shantha Biotech, Granules India, Natco Pharma, GVK
Biosciences
Bengaluru Biocon, Micro, Strides, GSK,Advinus, AstraZeneca, Aurigene, Avesthagen, Bal Pharma, Biozeen, Bayir Group, Bhat
Bio-tech, Camson Bio technologies, Global Calcium, Indigene Life system
New Delhi Ranbaxy, Panacea, Jubilant Life Sciences, Advanced Life Sciences, Akum Drugs & Pharma, Dr. Lal Path Labs,
JagsonPal Pharma, Life Medicare & Biotech, Mankind Pharma, Medicamen Biotech, ModiMundi Pharma, More
pen, Nestor Pharma, Ozone Pharma & Ayurvedic
Chennai Orchid, Shashun, Tablets India, TTK Healthcare, Amrutanjan Health care, Arvind Remedies, Axon Drugs, Bafna,
Caplin Point Labs, Cholayil, Fourrts India Labs, Life Cell International, Malladi Drugs & Pharma, Medopharm,
Nutra Specialities
Pune Bilcare, Serum India, Advinus Emcure, Acoris Research, Hindustan Antibiotics, National Chemical Lab, Vlife
Sciences
Navi Mumbai Reliance Life Science, Pfizer India, Wanbury, Alkem Pharma, Lilac Medicare, Thyrocare Technologies
Source: IndiaBioscience.org
The Indian Diverse geography caters to many Life Science business centres in India
10

City Major Companies
Chandigarh Surya Pharma, Nectar Life Sciences, Ind-Swift Labs
Vishakhapatnam Falcon Biotech, Vijaynagar Biotech Ltd, Actimus Biosciences Pvt.Ltd, Eisai Pharmatechnolgy Ltd, Techno
med systems
Baroda Alembic Pharma, Ambrosia Ltd, Divine Laboratories, Hindustan Biosynth Ltd, Sterling Biotech Unicure
Remedies
Noida & Gurgaon Ranbaxy Labs, Jubilant Life Sciences
Thane Aarti Drugs, Calyx Chemicals & Pharmaceuticals Ltd, Kremoint Pharma, Herbert Brown Pharmaceuticals &
Research
Kolkata Adinath Bio-Labs, Allister Biotech, Krish Biotech, Allen India Ltd, Albert David Ltd, East India
Pharmaceuticals Works, Emami, TCG Lifesciences
Indore Alpa Laboratories, Syncom Healthcare, Biofil Chemicals & Pharmaceuticals Ltd, Cyano Pharma, Parenteral
Drugs India Ltd
Source: IndiaBioscience.org
The Indian Diverse geography caters to many Life Science business centres in India
Majority of Indian states host Life Science business centres in India (2/2)
11

City Centres
New Delhi All India Institute of Medical Sciences,
Institute of Genomics and Integrative Biology, (IGIB)
National Institute of Immunology, Institute of Cytology and Preventive
Oncology (ICPO)
 International Centre for Genetic Engineering &
Biotechnology (ICGEB)
 Jawaharlal Nehru University
TERI University, Nizam's Institute of Medical Sciences
Bengaluru National Centre for Biological Science (NCBS) , National Institute of
Mental Health and Neurosciences
Stem Cell Institute
University of Agricultural Sciences, Jawaharlal Nehru
Centre for Advanced Scientific Research, Indian Institute of
Science (IISc)
Hyderabad Ashoka Trust for Ecology and the Environment
 International Crops Research Institute for the Semi-Arid Tropics
(ICRISAT)
 Centre for Cellular and Molecular Biology (CCMB)
 LV PRASAD EYE INSTITUTE
 National Institute for Nutrition
Indian Institute of Chemical Technology
Pune Agarkar Research Institute
Indian Institute of Science Education and Research
National Chemical Laboratory (NCL)
 National AIDS Research Institute (NARI)
,National Institute of Virology (NIV),
Microbial Containment Complex
The National Centre for Cell Sciences
Mumbai Advanced Centre for Treatment
Research and Education in Cancer
Bhabha Atomic Research Centre (BARC)
Bombay Natural History Society
Indian Institute of Technology Bombay (IIT- Bombay)
Tata Institute of Fundamental Research (TIFR)
 University of Mumbai
Ahmedabad National Institute of Pharmaceutical Education and Research (NIPER)
National Institute of Occupational Health (NIOH)
The Gujarat Cancer & Research Institute
Institute for Plasma Research
Indian Institute of Management Ahmedabad (IIM-A)
India has active Public and Private Institutes focused on research
covering spectrum of Lifesciences (1/2) (Few centers listed below)
12

City Centres
Kolkata Bose Institute
Indian Institute of Chemical Biology
Indian Statistical Institute
Jadavpur University
University of Calcutta
Indian Institute of Science Education and Research
Calcutta Medical Research Institute
Marine Engineering & Research Institute
Indian Institute of Management (IIM- C)
Nagpur Central Institute for Cotton Research
National Research Centre for Citrus (NRCC)
Indian Bureau of Mines
National Bureau of Soil Survey and Land Use Planning
National Environmental Engineering Research Institute (NEERI)
National Institute of Intellectual Property Management (NIIPM)
Lucknow Birbal Sahni Institute of Palaeobotany
Central Drug Research Institute
National Botanical Research Institute
Industrial Toxicology Research Centre (ITRC)
Indian Institute of Sugarcane Research (IISR)
Chennai Indian Institute of Technology Madras
University of Madras
National Institute for Research in Tuberculosis
The National Institute of Epidemiology (NIE)
CENTRAL LEATHER RESEARCH INSTITUTE (CLRI)
India has active Public and Private Institutes focused on research
covering spectrum of Lifesciences (2/2) (Few centers listed below)
13

14
India Co. USA Co.
Deal Size
(USD Mn)
Year Remarks
Wipro Health plan 460 2016
HealthPlan Services is a Leading Technology and Business Process as a
Service Provider in the US Health Insurance Market
Strides J&J N/A 2016 received CCI approval to acquire 7 brands from Johnson and Johnson
SRF Dupont 20 .0 2015 Pharma propellant business
Lupin Gavis 880 2015 Expand US generic
Torrent Pharma Zyg Pharma N/A 2015 Expand derma business in US
Cipla
InvaGen Pharma &
Exelan Pharma
550 2015 To boost its US business
Sun Pharma InSite Vision Inc 50 2015
The acquisition was completed by means of a short-form merger under the
Delaware law
Piramal OPIL & MSD BV 15 2015 acquisition of five trademark rights for India
Piramal
Coldstream
Laboratories
30.65 2015 Injectable market segment
Aurobindo Natrol Inc. 132.5 2014 Nutraceuticals platform for US & ROW
Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business
Kemwell Cirrus N/A 2013 Products with faster time-to-clinic and cost savings for customers

15
US Companies
Indian
Companies
Deal Size (USD
Mn)
Year Remarks
Mylan Famy Care 800 2015 Global women's health care
Quantum
solutions
Parexel N/A 2015
Create greater scale in service area, and provide comprehensive and efficient
solution to global clients.
Hospira Orchid Pharma 200 2014 API supplier for key antibiotics and future API development.
Carlyle Group Bharat Serum 83 2014 25-30% stake from existing investors.
Amneal Pharma Epsilon Pharma 16 2014
Expand footprint in India. Includes 200,000 + sf. US FDA certified
manufacturing facility.
Mylan Agila 1,600 2013 Become top-three global player in injectable
India Co. USA Co. Year Remarks
Ami Organics Photolitec 2015 Clinical trials to determine cancer treatments safety and and efficacy.
Emami Hevert-Arzneimittel 2014
Launched products via 400 homoeopathy medicine retail outlets across
diverse distribution channels via Emami.
Agila Biotech Pfenex Inc 2013
Develop, manufacture and commercialize initial pipeline of 6 biosimilar
products. AB = 51% equity stakeholder
USA - India – Joint Ventures

16
USA Companies
India
Companies
Year Remarks
Lab Pisa Biocon 2016 co-development & commercialization agreement for rh- Insulin in USA
BioQ Pharm Cipla 2016 agreement to commercialize BioQ's Ropivacaine Infusion System in India
Cyclopharm Jubilant 2015
Jubilant's subsidiary DraxImage signs pact with Cyclopharm to market Technegas in US.
DraxImage will provide up to $4.5M USD to fund the USFDA clinical trial , and also pay 17.5%
royalty.
Golden Helix MedGenome 2015 better tailor diagnostic and therapeutic strategies to individual patients.
Phyto Biotech Hysun Inc 2015 Hysun Inc forays into India market through partnership with India based Phyto Biotech
Oncobiologics Ipca Labs 2014 Development, manufacture and commercialization of biosimilar monoclonal antibodies.
BioQuiddity Cipla 2014
Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications for post-
surgical pain management.
Endo Pharma GVK Bio 2013
Novel small molecules. GVK BIO will use discovery expertise and Endo will
develop/commercialize product.
Moffitt Cancer
Centre
Advinus 2013 New oncology therapies.
Onconova
Therapeutics GVK Bio 2013 US JV to move Onconova oncology assets from early discovery to clinical development stage.
Novavax Cadila 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.

17
USA Companies India Companies Year Remarks
Fidelity Growth MedWell Ventures 2015
Fidelity Growth Partners invest USD 10 Mn in India based Medwell Ventures, with
plans to expand rapidly across the country
US Market
Glenmark 2014 Greenfield facility for US market for USD 100 Mn
Chase Pharma
Cipla 2014 Alzheimer’s drug development. Part of $21 M investment through syndicate
Oncobiologics Strides 2014 Strategic stake
US Market Lupin 2014
2 new US R&D Centres on inhalation and complex formulations research for USD
177.5 Mn
 During FY 2015, India received the FDI equity inflow from USA of ₹228 billion
(USD 3.51 billion). Commitment of US$42billion (2015-2017) from USA
organisations.
US – INDIA - Foreign Direct Investments

18
USA Co. India Co. Year Remarks
Xenoport Dr. Reddy’s 2016
enters US licensing agreement for development and commercialization of a clinical-stage oral new
chemical entity
Natera MedGenome 2015 Exclusive license to develop Natera's Panorama.
Gilead
Strides
Arcolabs
2015
Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license extends to
112 countries
Gilead Natco India 2015 Generic versions of chronic hepatitis C medicines.
Visterra Serum 2015
license agreement for a humanized monoclonal antibody.Deal value approx. USD 40 million excluding
royalties
Fresenius Kabi Caplin Point 2015
Caplin Point receive milestone payments for licensing agreements with Fresenius Kabi USA, and Cycle
Pharma, UK
Taxus Cardium Dr. Reddy’s 2015 Announces licensing agreement
Epirus Ranbaxy 2014 Infliximab (arthritis) with annual sales of $6 billion..
Merck Sun Pharma 2014 Worldwide rights to tildrakizumab. $ 280 M Deal
Cytosorbents Biocon 2014
Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications for India and
select emerging countries.
India from USA – Licensing deals

The Evolution Of India’s Patent Law
India’s Approach To Patentability Standards
Compulsory Licensing
Patent Linkage And Data Exclusivity
Pharma Economics In The Rich And Lesser Rich
Worlds
Emerging Challenges
The Road Ahead
INDIA- IPR Regime (ref: India IPR Report Aug 2015)
19

 The time limit given for submitting the application for grant has been
reduced to 4 months from 12 months, providing an extension of 2
months
 Necessary permissions to be taken from the concerned authority before
the grant of patents
 The introduction of product patents in India in 2005 gave a boost to the
discovery of new drugs
 India reiterated its commitment to IP protection following the
introduction of product patents
INDIA- Draft Patents (Amendment) Rules, 2015
20

 India's stance is that the current patent regime is
fully TRIPs compliant, striking the appropriate
balance between the grant of monopoly patent
rights and public health imperatives
 IPA presented data to suggest that the gulf
between US and Indian patent regimes may not
be as wide as perceived in terms of outcomes for
patentees.
 Several collaboration deals between US firms and
domestic companies including,
 Amgen - Dr Reddy's to distribute Amgen's oncology and
cardiology medicines,
 Gilead's licensing agreement with companies for hep C
generic medicines,
 Merck and Sun Pharma for tildrakizumab, and Boehringer
Ingelheim India with Lupin for linagliptin,
INDIA-Strengthening the Patent Office
 Supreme Court has interpreted the Patents Act
to remove apprehensions of abusive multiplicity
of challenges to the validity of a patent
 Important legislation is now in place to speed up
resolution of commercial disputes, including
those relating to intellectual property rights.
 Some long-standing substantive grievances of US
companies relating to India's IPR regime remain.
 Mainly compulsory licensing provision, prohibition
on grant of patents to new forms of known
substances without therapeutic benefit.
 US innovator companies are also concerned by the
alleged lack of data exclusivity.
Specific steps have already been taken; MNCs are collaborating with companies in several ways above to increase
access in the Indian market.
Souce: http://timesofindia.indiatimes.com/business/india-business/US-pharma-
body-slams-Indian-patent-regime/articleshow/50908408.cms>
21

 Many US-based companies, are trying to
evergreen their patents through cosmetic
changes, and applying for fresh patents. But
they have been largely unsuccessful in India
http://www.autonews.com/apps/pbcs.dll/article?AID=/200306
16/SUB/306160708/landmark-patent-case-broke-seldens-lock-
on-auto-industry
 A special provision in the Indian Patents Act,
Section 3 (d), allows the Indian Patents
Controller to
 Deny patents on items that are not significantly
different from their older versions.
 Low cost generic medicines manufactured in
India have been making medical care affordable
for millions in Africa and Latin America, not to
mention the US itself.
“Criticism of India’s IPR regime is best ignored”
 The powerful US pharmaceutical lobby has a
problem with Indian pharma producers, who have
managed to serve the poor not just in India but
across the world.
 It also does not want compulsory licenses to be
issued for manufacture of copies of patented drugs
to address situations of national emergency, as
permitted by the TRIPS agreement.
 Placed in the ‘priority watch’ list of countries that
(according to the US)need to tighten their IP laws.
 Through its Special 301 report, the US is trying to
push India to drop Section 3 (d).
 With the multilateral trade laws on India’s side
and the interest of millions of poor, USTR’s efforts
should be ignored or laughed off
Source: http://www.thehindubusinessline.com/opinion/columns/us-on-its-own-trip/article8576022.ece22

23
Business Cultural Differences sample
Meanings of Phrases and points in the US vs IN
 As Soon as Possible: ASAP vs ASAP
 Tomorrow: Next day vs In near future
 Will be done: surely be done vs will try best
 Business focus: Specialist vs Generalist
 Work driven by: Process vs Ad Hoc
 Everyday working: MBO vs MBC
 Business Transaction: Contractual vs Trust base
 Importance: Transaction vs Relationship
 Relationship: Short Term vs Long Term

Benefits to companies Collaborating with Indian Companies
Source: India Pharma Inc. Enhancing value through alliances and
Partnerships – Pharma Summit- 2011(PwC & CII Report)
 Pharma MNCs collaborating with Indian companies bring to table
new products, latest technology, higher investments, quality systems
and the knowledge of regulatory process
 On their part, Indian companies provide local market knowledge,
cost advantage and local scientific talents.
 Such alliances have the potential to bring significant benefits to both
parties and value to society as a whole. Such partnership bring in
new drugs and therapies to the market and increase patient's
awareness about diseases and wider treatment choices available
>> Lilly is currently transforming itself from a traditional fully integrated
pharmaceutical company into a fully integrated pharmaceutical network,
so that it can draw on a range of resources beyond its own walls.
>> Lilly hopes teaming up with the other organization to create virtual R&D
programmes will enable it to get better access innovation, reduce costs,
manage risks more efficiently and enhance productivity. For example, the
Chorus project is a virtual organization to take molecules quickly to proof
of concept.
>> Lilly also uses external networks comprising third parties such as
Piramal Life Science, Hutchinson MediPharma, and Suven Life Science in
the development of molecules
Enhancing value through alliances and Partnerships
24

25
Aagami, Inc.
A life sciences consulting firm based in the suburbs of Chicago
offers services in
For Global Biotech, Pharmaceutical , Medical Devices, Consumer
Health products companies, Universities, in their initiatives with US,
India, Asia, Brazil, Latin America and Emerging Markets.
Strategic Consulting
Technology Licensing
Market Intelligence

26
Strategic Consulting Services
 In-Licensing
 Out-Licensing
 Co-Development and Partnerships
 Investments to and from US/India/Asia/Brazil/Latin America
 Mergers & Acquisitions
 Finding the Right Partners
 JV and/or Distributors/ Contract Sales/Marketing/Contract Manufacturing,
CRO and CRAMS providers
 New Market Entry Strategy/ Development

27
Aagami brings
 Deep Understanding of business and socio-cultural differences in
ways of working.
 Extensive network with Top LifeSciences companies at C levels
 Global Deal experience.
 Aagami Partners bring value of combined experience of over 150
years.
 Focus on client needs, objectives, success and work as an extension of
client’s own team.

28
International
Phosphagenics Australia
PeptiSyntha Belgium
DelMar Pharma Canada
Affitech Denmark
Pieris Germany
Merus Holland
Venus Remedies India
Opsona Ireland
Toppan Japan
Otago University New Zealand
Aagami has completed over 100 assignments for more than 60 clients in the last 13+ years.
United States
Advangene IL
Loyola Univ. Chicago IL
Dow Chemicals MI
ScyFIX MN
OncBioMune LA
Penwest Corp. NY
DesignMedix OR
PLx TX
CreAgri CA
New Heaven Pharma CT
Sample list of Aagami Clients

29
Sample of Aagami Connectivity in India
We have a working relationship at C Level of TOP 100 Lifesciences companies
in India. Some of the popular names are below.
Biocon Intas Sun Pharma
Cadila Lupin Themis
Cipla MicroLabs Torrent Pharma
Dr Reddys Piramal USV
Glenmark Reliance Wockhardt
Hetero Drugs Strides Zydus

USA (Head Office)
Aagami, Inc.
2135 City Gate Lane Suite 300
Naperville, IL 60653
P: +1-630-364-1837
INDIA
Aagami
741, Nelson Square
Nagpur – 440013
P: +91-712-258-6678
Dinesh Jain
Email: dinesh@aagami.com
M: +1 630-853-3520
Godwyn Francis
Email: godwyn@aagami.com
M: +91-787-501-6957
www.aagami.com
30
Realizing Possibilities, Together
CONTACT US

Presentation made by Aagami during Illinois Science and Technology Park Event

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Presentation made by Aagami during Illinois Science and Technology Park Event

Similar to Presentation made by Aagami during Illinois Science and Technology Park Event (20)

More from Aagami, Inc.

More from Aagami, Inc. (19)

Recently uploaded

Recently uploaded (20)

Presentation made by Aagami during Illinois Science and Technology Park Event